Approval · Notice of Compliance 26662 · 2021
DEXILANT: Notice of Compliance 26662
Issued September 16, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26662
- Date
- September 16, 2021
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- To update the Product Monograph (PM) following an update to the Company Core Data Sheet and response to an Advisement Letter. Update the PM to the 2020 Master Template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DEXILANT | Not yet assigned | — |
Medicinal ingredients
- DEXLANSOPRAZOLE 30 MG per CAP
- DEXLANSOPRAZOLE 60 MG per CAP